Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Utilization of NBi in Assessing Luminal INflammaion in IBD (UNBLIND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02049775
Recruitment Status : Unknown
Verified February 2016 by The Leeds Teaching Hospitals NHS Trust.
Recruitment status was:  Recruiting
First Posted : January 30, 2014
Last Update Posted : February 19, 2016
Information provided by (Responsible Party):
The Leeds Teaching Hospitals NHS Trust

Brief Summary:

Ulcerative colitis (UC) is a chronic inflammatory condition of unknown aetiology, characterized by a diffuse confluent mucosal inflammation of the colon starting from the rectum with a relapsing and remitting course. Conventional endoscopy was thought to be a reliable parameter of disease activity, but microscopic inflammation can persist despite normal mucosal findings. Histologically detectable inflammation is associated with a greater risk of subsequent relapse. A flare in UC activity is difficult to predict, but a simple, easily measured biological marker of relapse would be important in guiding the most appropriate therapy.

Recent technological advances in fiber optics, light sources, detectors, and molecular biology have stimulated development of numerous optical methods that promise to significantly improve our ability to evaluate human epithelium in vivo. These methods, collectively termed "optical biopsy," are nondestructive in situ assays of mucosal histopathology using light that can provide instantaneous tissue assessment. Narrow band imaging (NBI) is a novel technique that enhances the diagnostic capability of endoscopes in characterising tissues by using filters in a redgreenblue (RGB) sequential illumination system. This results in improved mucosal contrast and detail.

UC always involves the distal colon and activity is usually greatest in rectosigmoid area. This makes evaluation of the rectum and sigmoid an attractive marker in patients with UC. Unlike serum and faecal markers, endoscopic assessment of the mucosa is unlikely to be affected by systemic disease and would be acceptable test for patients and physicians.

We plan to evaluate THE rectosigmoid mucosa in patients with UC by flexible endoscope using both white light and NBI endoscopy. These patients will be followed by for one year or until they relapse, whichever comes first. The aim of our study is to develop endoscopic biomarkers to predict relapse in acute and quiescent UC.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis (UC) Procedure: NBI Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Utility of Narrow Band Endoscopy in Predicting Short and Long Term Risk of Relapse in Patients With Quiescent Ulcerative Colitis
Study Start Date : April 2013
Actual Primary Completion Date : April 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: NBI Procedure: NBI

Primary Outcome Measures :
  1. Narrow band imaging (NBI) [ Time Frame: up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Adult patients referred for lower gastrointestinal endoscopy procedure will be recruited.
  • Any age (1885 years), gender or ethnic background
  • Able and willing to give an informed consent

Exclusion Criteria:

  • Patients known to be intolerant to endoscopy.
  • Patients with severe lifethreatening comorbidity as judged by the investigator.
  • Patients on therapy with anticoagulation that may preclude taking any biopsies
  • Pregnant women or breast feeding mothers
  • Patient with toxic megacolon
  • patients on medications known to cause bowel inflammation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02049775

Layout table for location contacts
Contact: Venkataraman Subramanian, MD, MRCP 01132068822

Layout table for location information
United Kingdom
Leeds Teaching Hospital NHS Trust Recruiting
Leeds, United Kingdom, LS9 7TF
Contact: Venkataraman Subramanian, MD, MRCP    01132068822   
Sponsors and Collaborators
The Leeds Teaching Hospitals NHS Trust
Layout table for additonal information
Responsible Party: The Leeds Teaching Hospitals NHS Trust Identifier: NCT02049775    
Other Study ID Numbers: UR13/10708
First Posted: January 30, 2014    Key Record Dates
Last Update Posted: February 19, 2016
Last Verified: February 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases